Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MegKal
- Development stage
- Unknown
- Lead developer
- Bion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MegKal is an oral nutraceutical combination tablet developed by Bion Therapeutics, specifically formulated to support women's health, bone density, and cardiovascular wellness. It contains calcium carbonate (providing elemental calcium), cholecalciferol (vitamin D3), and menadione (vitamin K3). Calcium carbonate serves as a primary mineral source for bone mineralization, while cholecalciferol enhances intestinal calcium absorption by activating the vitamin D receptor (VDR). Menadione acts as a cofactor for gamma-glutamyl carboxylase (GGCX), facilitating the carboxylation of osteocalcin and matrix Gla protein, which helps direct calcium to the bones and prevents vascular calcification. MegKal is marketed in India for the prevention and treatment of calcium and vitamin D deficiencies, osteopenia, and osteoporosis, particularly in women.
- Brand names
- MegKal
- Other names
- calcium carbonate + cholecalciferol + menadionecalcium carbonate + cholecalciferol + vitamin K3calcium carbonate + vitamin D3 + vitamin K3
02
Targets
CaSR (Extracellular calcium-sensing receptor)GGCX (Vitamin K-dependent gamma-glutamyl carboxylase)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on MegKal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MegKal.